Bremelanotide - Palatin Technologies

Drug Profile

Bremelanotide - Palatin Technologies

Alternative Names: PT-141; RekyndaTM

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Arizona
  • Developer Palatin Technologies; Simons Foundations
  • Class Cyclic peptides; Erectile dysfunction therapies; Hypothalamic hormones; Melanocyte-stimulating hormones
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Female sexual dysfunction
  • Phase II Cognition disorders
  • No development reported Erectile dysfunction
  • Discontinued Haemorrhagic shock; Vascular disorders

Most Recent Events

  • 04 Jun 2018 AMAG Pharmaceuticals intends to launch bremelanotide in USA in early 2019
  • 04 Jun 2018 FDA assigns PDUFA action date of 23/03/2019 for bremelanotide for Hypoactive sexual desire disorder
  • 04 Jun 2018 The US FDA accepts NDA for bremelanotide for Hypoactive sexual desire disorder for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top